Limits...
Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials.

Sajid MS, Hebbar M, Baig MK, Li A, Philipose Z - J Neurogastroenterol Motil (2016)

Bottom Line: Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18-0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11-0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22-0.44; P = 0.00001]).The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to -2.27; P = 0.0004]) in prucalopride group.Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation.

View Article: PubMed Central - PubMed

Affiliation: Department of General, Endoscopic and Laparoscopic Colorectal Surgery, Western Sussex Hospitals NHS Foundation Trust, Worthing Hospital, Worthing, UK.

ABSTRACT
This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride in patients with chronic constipation. Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18-0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11-0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22-0.44; P = 0.00001]). The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to -2.27; P = 0.0004]) in prucalopride group. Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation.

No MeSH data available.


Related in: MedlinePlus

Forest plot for reduced spontaneous bowel movement after 2 mg versus placebo in patients with chronic constipation. Combined outcome is expressed as standardized mean difference.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4930296&req=5

f5-jnm-22-412: Forest plot for reduced spontaneous bowel movement after 2 mg versus placebo in patients with chronic constipation. Combined outcome is expressed as standardized mean difference.

Mentions: Nine included trials (Fig. 5) contributed to the combined calculation of this variable. There was significant heterogeneity (Tau2 = 0.07; Chi2 = 36.40, df = 8 [P = 0.0001]; I2 = 78%) among the trials. In the random effects model (SMD, 0.34; 95% CI, 0.11–0.56; z = 2.94; P = 0.003), there was a higher risk of reduced SBMs per week in the placebo group and subsequently the frequency of SBMs per week was higher following the use of 2 mg prucalopride to treat chronic constipation.


Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials.

Sajid MS, Hebbar M, Baig MK, Li A, Philipose Z - J Neurogastroenterol Motil (2016)

Forest plot for reduced spontaneous bowel movement after 2 mg versus placebo in patients with chronic constipation. Combined outcome is expressed as standardized mean difference.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4930296&req=5

f5-jnm-22-412: Forest plot for reduced spontaneous bowel movement after 2 mg versus placebo in patients with chronic constipation. Combined outcome is expressed as standardized mean difference.
Mentions: Nine included trials (Fig. 5) contributed to the combined calculation of this variable. There was significant heterogeneity (Tau2 = 0.07; Chi2 = 36.40, df = 8 [P = 0.0001]; I2 = 78%) among the trials. In the random effects model (SMD, 0.34; 95% CI, 0.11–0.56; z = 2.94; P = 0.003), there was a higher risk of reduced SBMs per week in the placebo group and subsequently the frequency of SBMs per week was higher following the use of 2 mg prucalopride to treat chronic constipation.

Bottom Line: Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18-0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11-0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22-0.44; P = 0.00001]).The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to -2.27; P = 0.0004]) in prucalopride group.Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation.

View Article: PubMed Central - PubMed

Affiliation: Department of General, Endoscopic and Laparoscopic Colorectal Surgery, Western Sussex Hospitals NHS Foundation Trust, Worthing Hospital, Worthing, UK.

ABSTRACT
This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride in patients with chronic constipation. Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18-0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11-0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22-0.44; P = 0.00001]). The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to -2.27; P = 0.0004]) in prucalopride group. Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation.

No MeSH data available.


Related in: MedlinePlus